Crossbeta gains new ceo and funding
Dutch biotech to advance technology in several therapeutic areas
Scheefhals has joined the biotech firm from Avantium, where he held several managerial positions, most recently as chief operating officer of the pharma business unit. Prior to Avantium, he held commercial positions at DSM Biologics, Analytico and NPBI, which is now part of Fresenius.
Scheefhals replaces Johan Renes, who steps down after being with the company from the start and for the past two years as part-time ceo.
Crossbeta has recently won funding of €2m, which will be used to advance the firm’s technology in several therapeutic areas and to establish a stronger position for co-development programmes and commercialisation partnerships.
You may also like
Drug Delivery
Bio-Sourcing and Zerion Pharma secure Eurostars funding to develop HER2 oral monoclonal antibody
The pair have been awarded a €1.3m Eurostars grant to develop an oral formulation of the anti-HER2 monoclonal antibody trastuzumab for breast cancer, combining Bio-Sourcing’s BioMilk platform with Zerion’s Dispersome technology to advance the candidate through preclinical development
Research & Development
FairJourney Bio launches cryo-EM services to support antibody discovery and biologics design
The new offering at the company's San Diego laboratories provides high-resolution structural insights to accelerate antibody discovery, selection and optimisation across the biologics R&D pipeline
Research & Development
Studies on HIV and TB reveal tradeoffs for both viruses and immune system in race to survive
Research teams have identified mechanisms by which HIV can evade lenacapavir, at the cost of the virus's reproduction and how the immune system can use bacteria to protect against infection — until TB evolved to take advantage
Research & Development
Enara Bio expands Boehringer Ingelheim partnership as DARKFOX programme moves toward the clinic
Enara Bio has entered 2026 with renewed momentum after Boehringer Ingelheim licensed additional Dark Antigen targets under their oncology collaboration. The company is also continuing to expand its EDAPT discovery platform
Research & Development
Early stage clinical trials highlight the convergence of novel therapeutics and enabling technologies
Early stage clinical development is increasingly being shaped by advances in drug discovery and the technologies and manufacturing strategies that enable the safe, precise and scalable delivery of new therapies
Research & Development
Breast cancer is the world’s most studied disease for fifth consecutive year according to analysis from Phesi
The US led global clinical trial activity in 2025 and across all top five indications, with China recording the fastest growth in the number of recruiting clinical trial sites